"The back and forth arguments are frustrating and, frankly, unacceptable"
USA: Still no clarity on rising insulin costsUS Congress Oversight and Investigations Subcommittee holds second hearing on the insulin pricing crisis in the US.
> Read more
News and insights brought to you by the International Diabetes Federation
With so little innovation for type 1 diabetes, new treatment options are a welcome change.
FDA weighs risks of new treatment for type 1 diabetesFDA to decide on approval of use of SGLT1/SGLT2 inhibitors in combination with insulin therapy.
> Read more- 1
- 2